Rational Development of a Polysaccharide–Protein‐Conjugated Nanoparticle Vaccine Against SARS‐CoV‐2 Variants and Streptococcus pneumoniae (Adv. Mater. 21/2022)
Source abstract
Abstract
Nanoparticle Vaccines In article number 2200443, Liangzhi Xie, Chengfeng Qin, and co-workers develop a novel bivalent nanoparticle vaccine that confers protection against infection of multiple SARS-CoV-2 variants and Streptococcus pneumoniae. This universal polysaccharide–protein-conjugated vaccine platform provides a powerful tool to fight against cocirculating viral and bacterial pathogens worldwide.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Advanced Drug Delivery Systems · SARS-CoV-2 and COVID-19 Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Virology State Key Laboratory of Pathogen and Biosecurity Beijing Institute of Microbiology and Epidemiology AMMS Beijing 100071 P. R. China
Beijing Protein and Antibody R&D Engineering Center Sinocelltech Ltd. Beijing 100176 P. R. China
Research Unit of Discovery and Tracing of Natural Focus Diseases Chinese Academy of Medical Sciences Beijing 100071 P. R. China
References
Reference metadata was not supplied for this record.